MarketCap
Facebook
X
TelegramAnnual report 2024
added 04-25-2026
Country |
 Canada |
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
- |
Market Cap[1] |
$ 18.4 M |
EBITDA (LTM) |
$ -13.8 M |
P/E (LTM) |
- |
P/S (LTM) |
195.6 |
EPS (LTM) |
-0.17 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market | Canada |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
- | 1.35 % | $ 17.8 M | Nasdaq Capital Market |  China |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American |  USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Coherus BioSciences
CHRS
|
$ 1.63 | -4.4 % | $ 191 M | Nasdaq Global Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market |  Britain |
 |
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.73 | -0.03 % | $ 33.4 M | Nasdaq Capital Market |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 7.83 | -5.21 % | $ 214 M | Nasdaq Global Market,SPB | Israel |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Esperion Therapeutics
ESPR
|
$ 3.12 | - | $ 649 M | Nasdaq Global Market,SPB | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market | Israel |
 |
Exelixis
EXEL
|
$ 51.1 | -0.37 % | $ 13.9 B | Nasdaq Global Select Market,SPB | USA |
|
Forte Biosciences
FBRX
|
$ 23.96 | -2.84 % | $ 310 M | Nasdaq Capital Market | USA |
|
Galera Therapeutics
GRTX
|
- | -32.59 % | $ 7.61 M | Nasdaq Global Market | USA |
 |
Karyopharm Therapeutics
KPTI
|
$ 8.9 | 0.56 % | $ 1.08 M | Nasdaq Global Select Market | USA |
 |
AbCellera Biologics
ABCL
|
$ 4.4 | -7.76 % | $ 1.31 B | Nasdaq Global Select Market | Canada |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 17.3 | -5.57 % | $ 809 M | Nasdaq Global Select Market | USA |
 |
BioNTech SE
BNTX
|
$ 91.99 | -0.26 % | $ 22.2 B | Nasdaq Global Select Market | Germany |
 |
Compugen Ltd.
CGEN
|
$ 3.03 | 6.32 % | $ 283 M | Nasdaq Global Market,SPB | Israel |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
Gilead Sciences
GILD
|
$ 132.06 | -0.74 % | $ 164 B | Nasdaq Global Select Market,SPB | USA |
 |
Genmab A/S
GMAB
|
$ 26.9 | 1.32 % | $ 1.74 B | Nasdaq Global Select Market |  Danmark |
 |
Genprex
GNPX
|
$ 0.86 | 1.2 % | $ 802 K | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.49 | -4.12 % | $ 5.75 M | NYSE American | Israel |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
Grifols, S.A.
GRFS
|
$ 7.79 | 1.04 % | $ 5.29 B | Nasdaq Global Select Market |  Spain |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Fortress Biotech
FBIO
|
$ 2.3 | 3.14 % | $ 64.2 M | Nasdaq Capital Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 21.57 | -0.55 % | $ 2.74 B | Nasdaq Global Select Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 9.24 | 36.48 % | $ 264 M | Nasdaq Capital Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.